Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases

NCT04647916 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT04647916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04647916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 8, 2021
Completion date
December 31, 2028
Enrollment
44 (estimated)
Sites
296

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, invasive breast carcinoma, metastatic her2 negative breast carcinoma, metastatic malignant neoplasm in the brain, prognostic stage iv breast cancer ajcc v8